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Abstract
Cognitive dysfunction is a common feature of autoimmune encephalitis. Pathogenic neuronal surface antibodies are
thought to mediate distinct profiles of cognitive impairment in both the acute and chronic phases of encephalitis. In
this review, we describe the cognitive impairment associated with each antibody-mediated syndrome and, using
evidence from imaging and animal studies, examine how the nature of the impairment relates to the underlying
neuroimmunological and receptor-based mechanisms. Neuronal surface antibodies, particularly serum NMDA receptor
antibodies, are also found outside of encephalitis although the clinical significance of this has yet to be fully
determined. We discuss evidence highlighting their prevalence, and association with cognitive outcomes, in a number
of common disorders including cancer and schizophrenia. We consider mechanisms, including blood-brain barrier
dysfunction, which could determine the impact of these antibodies outside encephalitis and account for much of the
clinical heterogeneity observed.
Introduction
An expanding array of pathogenic neuronal auto-
antibodies are being identified, each targeting different
neuronal surface antigens and thought to cause distinct
and clinically recognisable encephalitic syndromes. These
antigenic targets have wide-ranging properties and dis-
tributions in the central nervous system but common to
almost all autoimmune encephalitides is cognitive dys-
function. The nature of cognitive impairment and asso-
ciated neuroimaging findings varies between syndromes
and gives insight into the antibody-mediated mechanism
of action. Neuronal autoantibodies have also been
reported—so far mainly in the peripheral blood—in
individuals without frank encephalitis. Although their
significance outside the encephalitic context is not yet
clear, there is a growing body of evidence to suggest these
autoantibodies have pathogenic potential even in the
absence of the encephalitic syndrome. In this review, we
outline the cognitive profile of each of the commonest
autoantibody-mediated encephalitides and consider the
role of neuronal antibodies outside encephalitis. While a
treatment of the neurotransmitter basis of cognition is
beyond the scope of this review, it is important to note
that these autoantibodies largely serve to disrupt the
signalling transmission of neurotransmitters such as glu-
tamate and γ-aminobutyric acid (GABA) which are inte-
gral to cognition. Glutamate is a ubiquitously distributed
excitatory neurotransmitter that also acts as an inter-
mediary in cerebral metabolism; the ionotropic
glutamate-specific N-Methyl-d-aspartate receptor
(NMDAR) and α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) receptors are vital compo-
nents of long-term potentiation (LTP) and long-term
depression, processes understood to be the major synaptic
substrates of learning and memory; changes in the neu-
ronal surface density of these receptors therefore have
direct effects on neuronal signalling with downstream
impact on brain connectivity and cognitive processes.
GABA receptors are present as ionotropic (GABAA
receptor) and metabotropic (GABAB receptor) post-
synaptic receptors that are bound by GABA, the major
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inhibitory neurotransmitter in the central nervous system
(CNS). While long-range GABAergic neurons do exist,
the majority of research attention relevant to cognition
has focused on GABAergic interneurons, which appear to
have a central role in the synchronisation of network
activity and the generation of oscillations in different
frequency bands, processes felt to facilitate the efficacy of
information processing1.
Furthermore, the inhibitory-excitatory balance that is
emergent from dynamic interactions of glutamatergic and
GABAergic signalling is thought to play an important role
in stimulus representation and information propagation
and therefore is likely to be crucial not only for cognition
but for behavioural processes defined more broadly2,3.
Autoimmune encephalitis
Detailed neuropsychological characterisation is often
challenging in the acute phase of autoimmune encepha-
litis due to the severity of clinical symptoms. Accordingly,
in the acute phase clinical descriptions tend to be quali-
tative and the more extensive cognitive testing possible in
the post-acute and chronic phases is frequently authored
from a neurorehabilitation perspective, potentially intro-
ducing a selection bias towards cases with more severe
dysfunction. While we describe the acute and chronic
cognitive deficits separately, in practice such distinctions
are not so easily delineated and there is often significant
overlap. Table 1 summarises the cognitive impairment
associated with each neuronal autoantibody-associated
encephalitis. It is useful to note at the outset that while
most autoimmune encephalitides are named after the
putatively pathogenic antibody, there is increasing evi-
dence that there may be variability in the breadth of the
antibody response between these disorders; for example,
in LGI1 encephalitis the polyclonal antibody response
appears only to target the LGI1 protein4, whereas in
NMDAR encephalitis less than 10% of intrathecal
antibody-secreting cells are specific for the NR1 subunit
of the NMDAR5. This raises the possibility that antibodies
targeting other (non-canonical) epitopes, or even entirely
different proteins, may contribute to the clinical expres-
sion of disease in some disorders.
NMDAR encephalitis
Acute phase
NMDAR encephalitis is both the most common and
best-defined cause of autoimmune encephalitis. Its onset
is often heralded by an influenza-like prodrome followed
by a characteristic progression from psychotic symptoms
and cognitive impairment to seizures, movement disorder,
autonomic instability and loss of consciousness6. While
most frequently described in women of child-bearing age,
it is increasingly recognised in children and older adults of
both sexes6.
Cognitive dysfunction is often profound and in the
acute phase typically extends across all domains. Deficits
in executive function and memory are most marked but
attention, language, visuospatial processing and social
cognition are also affected to varying degrees7,8. Atypical,
unusual presentations of cognitive impairment are occa-
sionally described in NMDAR encephalitis; case reports
illustrate disruption to temporal orientation with a loss of
age awareness and also transient epileptic amnesia,
characterised by repeated, brief episodes of anterograde
and retrograde amnesia9,10. Another recent case report
documented a patient who, due to the nature of their
presentation with memory loss, cognitive fluctuations,
visual hallucinations and sleep disorder, was initially
misdiagnosed with Lewy Body Dementia before NMDAR
antibodies were identified leading to effective immu-
notherapy treatment11. In older adults with NMDAR
encephalitis cognitive impairment is often more promi-
nent which may account for some of the variability seen12.
Long term follow-up
While cognitive dysfunction is extensive in the acute
phase it can also persist for years after the initial insult13.
As in the acute phase, episodic memory and executive
function are most consistently affected 1 year after initial
presentation7,8,13,14. A recent systematic review found
chronic cognitive impairment in up to three quarters of
patients, with timely immunotherapy the most important
factor determining positive outcomes8. This emphasises
the persistent and major morbidity of cognitive impair-
ment in anti-NMDAR encephalitis for patients, in addi-
tion to the importance of early diagnosis and appropriate
treatment13.
Mechanisms underlying cognitive impairment
The NMDA receptor is a tetrameric ligand-gated ion
channel which mediates excitatory transmission in the
CNS and is crucial for LTP, the neural substrate for
learning and memory. In NMDAR encephalitis, there is
substantial intrathecal production of IgG NMDAR anti-
bodies which target the NR1 subunit of the receptor,
causing a reversible and titre-dependent internalisation of
the NMDA receptor with subsequent reduced receptor
density and reduction in NMDAR-mediated currents15,16.
The antibody-mediated disruption of the interaction
between the NMDA and ephrin-B2 receptor is central to
this, causing the NMDAR to become displaced which
allows subsequent internalisation17. Indeed, animal stu-
dies suggest that if ephrin-B2 is co-administered, the
pathogenic effects of the antibodies are blocked and no
downstream effects are seen18.
Accordingly, NMDAR-dependent LTP is depressed in
mouse hippocampal slices with prolonged exposure to
CSF from patients with NMDAR encephalitis19.
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Furthermore, in vivo infusion of NMDAR antibodies
reduces excitatory postsynaptic currents in rat hippo-
campal neurons and simultaneously impairs learning and
spatial working memory20. Infusion of inflammatory
cytokines also reduced excitatory postsynaptic currents
and led to further impairment in learning performance
suggesting there may be other additive factors influencing
cognitive dysfunction15. More recently, object recognition
has been shown to be impaired following injection of
NMDAR antibodies to rat hippocampi, widening the
application of NMDAR antibody-mediated cognitive dys-
function21. NMDAR antibodies cause a dose-dependent
increase in extracellular glutamate, akin to the elevated
level of glutamate following ketamine administration
which is associated with cognitive effects22.
NMDARs are highly concentrated in the hippocampus
and frontal cortex which likely underlies the pre-
dominance of cognitive deficits in episodic memory and
executive function23. Indeed, reduced functional con-
nectivity between the hippocampus and the medial pre-
frontal cortex and impaired connectivity within the medial
temporal lobe (MTL) network was observed in patients
with NMDAR encephalitis and shown to predict the
severity of memory impairment (Fig. 1)24,25. Furthermore,
although the disorder is not a classical limbic encephalitis,
in the post-acute phase reduced bilateral hippocampal
volume and microstructural integrity is observed, which
likewise correlates with memory impairment26. Wide-
spread damage to superficial white matter – which
encompasses short-range association fibres and intracor-
tical myelin—additionally contributes to impairments of
attention and memory27, and extensive changes in deep
white matter integrity correlate with disease severity24.
This structural damage to hippocampus and white matter
suggests pathological mechanisms ongoing beyond the
demonstrated reversible internalisation of NMDAR with-
out damage to neurons;16,26 T cell mediated processes may
have an as-yet under-appreciated role here28.
Encephalitis formerly attributed to antibodies to the
voltage gated potassium channel (VGKC): LGI1 and
CASPR2 encephalitis
The first potentially reversible, immunosuppression-
responsive form of limbic encephalitis was described
nearly 20 years ago29. The VGKC antibodies originally
detected were believed to directly target the Kv1.1, 1.2 and
1.6 channels. However, it is now understood that patho-
logical VGKC antibodies target the extracellular domains
of one or more of three proteins tightly complexed with
VGKCs; LGI1, CASPR2 and contactin-2, each with dif-
ferent implications30. “Double negative” VGKC antibodies
—that is VGKC antibody positivity without LGI1 or
CASPR2 positivity—are of questionable clinical sig-
nificance (potentially targeting intracellular targets) and
for this reason VGKC antibodies should not be routinely
tested in the initial investigation of a patient with a sus-
pected autoimmune CNS disorder31,32.
LGI1 encephalitis
Acute phase
Typical presenting symptoms of LGI1 encephalitis are
those of a limbic encephalitis; symptoms include cognitive
impairment, behavioural changes and focal seizures. Sei-
zures typically precede the onset of cognitive impairment,
with a progressive amnesia usually developing at their
crescendo33. Unlike other autoimmune encephalitides
(and most autoimmune conditions) LGI1 encephalitis is
most common in middle-aged males. Although LGI1
encephalitis is phenotypically similar to other para-
neoplastic and non-paraneoplastic limbic encephalitides,
faciobrachial dystonic seizures (FBDS) are unique to LGI1
encephalitis and are a useful clinical differentiator34.
Prominent amnesia is a hallmark of limbic encephalitis
associated with LGI1-antibodies; autobiographical memory
is particularly impaired, often with significant confusion and
disorientation30,35,36. Isolated amnestic syndrome can occur
in up to 10% of cases of LGI1 encephalitis35 and, in the
absence of seizures and where the onset is insidious, LGI1
encephalitis can mimic other syndromes of cognitive
impairment such as neurodegenerative dementias37. Indeed,
numerous case reports have documented LGI1 encephalitis
misdiagnosed as Alzheimer’s disease, Creutzfeld-Jacob
Disease and Dementia with Lewy Bodies before further
investigation elucidated the true cause and led to reversal of
the cognitive impairment with immunotherapy38.
Long term follow-up
Looking at long term outcomes for patients with pre-
viously defined VGKC antibodies collectively, without
differentiating LGI1 or CASPR2-positive patients, cogni-
tive deficits correlate with antibody titre and are most
marked for verbal memory, while processing speed and
executive function are relatively spared39. In LGI1 ence-
phalitis, most patients have a chronic cognitive impair-
ment, with memory predominantly affected but deficits of
attention and executive function also reported40–42.
Greater disease severity, delays to immunotherapy or
longer courses of immunotherapy (likely mandated by
greater disease severity) are all associated with more pro-
found cognitive dysfunction in LGI1 encephalitis40. Indeed,
early treatment of isolated FBDS significantly reduces the
risk of developing cognitive impairment, highlighting the
importance of recognising FBDS early43,44.
Mechanisms underlying cognitive impairment
Unlike NMDAR antibodies, LGI1 antibodies are pre-
dominantly of the IgG4 subclass, although the
IgG1 subclass may also contribute to pathology. LGI1 is a
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Fig. 1 (See legend on next page.)
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trans-synaptic protein which complexes presynaptic
ADAM23 with postsynaptic ADAM22. LGI1 antibodies
act directly to disrupt this binding which subsequently
reduces synaptic AMPAR density45. However, given the
marked differences in clinical presentation with AMPAR
encephalitis, it is likely that LGI1 antibodies have other
downstream effects in addition to modulation of
AMPARs. In one study of 103 patients, IgG1 antibodies
occurred more frequently in patients with cognitive
impairment, suggesting a role for complement-mediated
pathology in this symptom domain43. Serum IgG VGKC
antibodies from patients with limbic encephalitis led to
cell excitability with an increased tonic rate of firing and
strengthened mossy fibre-evoked synaptic responses in
CA3 rat hippocampal slices—the sera used in this study
was later found to have LGI1 rather than CASPR2 anti-
bodies46. A selective VGKC antagonist mimicked these
effects suggesting that the antibody-mediated increase in
cell excitability is directly related to reduction in VGKC
function. Petit-Pedrol et al. later demonstrated LGI1
antibody-mediated reductions in synaptic density of both
Kv1.1 VGKC and AMPAR receptors with simultaneous,
reversible memory deficits47. They observed hyperexcit-
ability, increased glutamatergic transmission and reduced
synaptic failure rate with a severe impairment to neuronal
plasticity and LTP in CA1 and the dentate gyrus. A recent
study further explored the pathogenic mechanisms of
LGI1-antibodies and suggested the possibility of syner-
gistic contributions. Monoclonal antibodies derived from
patients with LGI1-mediated disease were found to target
multiple epitopes, with distinct specificities to the pro-
tein’s LRR and EPTP-domains. In this study, LRR and
EPTP-binding LGI1 antibodies seemed to mediate dis-
tinct functional effects. LRR-directed antibodies bound
and internalised the LGI1-ADAM22/23 complexes. Sur-
prisingly, this mechanism was independent of IgG biva-
lency, as both IgG4 antibodies and Fab fragments retained
this capacity. The dominant effect of EPTP-binding
antibodies, on the other hand, appeared to be disruption
of the interaction between LGI1 and its receptors. Both
LRR- and EPTP-specific antibodies completely abrogated
LTP induction at CA3-CA1 hippocampal synapses, which
translated to impairment of recognition memory in mice
exposed to LRRP-antibodies48. These findings likely
explain the amnestic syndrome experienced by patients
with LGI1 encephalitis.
Interestingly, in humans, LGI1 gene mutations lead to
autosomal dominant lateral temporal lobe epilepsy char-
acterised by frequent partial seizures often with auditory
auras (rather than FBDS) but typically without cognitive
impairment49. This might relate to differences in the
timing of protein dysfunction (from early neurodevelop-
ment vs later in adult life) or to other in vivo roles of LGI1
and its targeting by autoantibodies that have not yet been
clearly defined.
In the rodent, LGI1 and CASPR2 are preferentially
expressed in CA3 and CA1 hippocampal subfields30,50.
Correspondingly, MR imaging in the acute phase of LGI1
or CASPR2 encephalitis is usually abnormal, typically
showing inflammation in MTL, an area critically involved
in memory processing51,52. At follow-up, almost all
patients show some degree of hippocampal atrophy,
which is often bilateral, with loss seen particularly in the
CA3 subfields40,53. The volumetric atrophy also correlates
with the severity of episodic autobiographical and verbal
memory impairments40,53. The microstructural integrity
of the hippocampus is also impaired on a wider level
which associates with both disease severity and memory
function; functional connectivity of the remaining hip-
pocampus correlates closely with the degree of memory
impairment40,54. Interestingly, functional connectivity
analyses also show characteristic alterations in several
large-scale networks, suggesting that LGI1 encephalitis is
not confined to the limbic system. Increased connectivity
in the ventral and dorsal default-mode network is asso-
ciated with improved memory performance, indicating a
(see figure on previous page)
Fig. 1 NMDAR encephalitis. a NMDAR-antibody access to the brain; b Molecular mechanisms of pathogenicity; c Functional effects of the NMDAR-
antibodies; d Functional connectivity changes in NMDAR encephalitis. (Left) Impaired functional connectivity between the hippocampus and the
medial prefrontal cortex identified using independent component analysis and dual regression. The severity of hippocampal functional connectivity
impairment correlates with individual memory deficits. (Middle) Impaired connectivity of the hippocampus with the medial prefrontal cortex
replicated using a seed-based approach. In addition, reduced hippocampal connectivity with other regions of the default mode network was
observed, e.g. the posterior cingulate cortex and the precuneus. (Right) Using a network-based approach, significantly reduced functional
connectivity was found within several large-scale networks, including the medial temporal lobe network, the sensorimotor network and the visual
network. [Figures reproduced with permission from24,25] e Clinical phenotype. LGI1 encephalitis: a Molecular mechanisms of pathogenicity;
b Functional effects of the LGI1-antibodies; c Patients with LGI1 encephalitis had increased functional connectivity of the dorsal and ventral default
mode network (DMN) that correlated with working memory (dorsal DMN) and episodic memory (ventral DMN) performance. [Figures reproduced
with permission from55]; d Clinical phenotype. CASPR2 encephalitis and Morvan’s Syndrome: a Molecular mechanisms of pathogenicity;
b Functional effects of the CASPR2-antibodies; c Bilateral FLAIR hyperintense signal and mild atrophy of the hippocampus in a patient with CASPR2
encephalitis; d Clinical phenotype. Components of this figure were created using Servier Medical Art templates, which are licensed under a Creative
Commons Attribution 3.0 Unported License; https://smart.servier.com. The shapes of the electrophysiological traces were modelled on data
published in47,61,147.
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compensatory mechanism, while connectivity in the sal-
ience network is reduced and correlated with impaired
memory function55. These network changes indicate
cognitive deficits beyond mere memory impairment in
LGI1 encephalitis, suggesting brain-wide alteration of the
connectome triggered by focal hippocampal damage.
CASPR2 encephalitis and Morvan’s syndrome
Acute phase
CASPR2 antibodies associate with a wide range of
neurological syndromes, which often overlap in the same
patient. Manifestations include peripheral nerve hyper-
excitability (often referred as neuromyotonia), neuro-
pathic pain, paroxysmal movement disorders and limbic
encephalitis56. Among the different CASPR2-related
syndromes, limbic encephalitis and Morvan’s syndrome
have a particular impact on cognitive functions. CASPR2
encephalitis, similarly to LGI1 encephalitis57, is char-
acterised by limbic dysfunction, with temporal seizures,
memory impairment and frontal dysfunction36. Morvan’s
syndrome, a rarer disorder, is characterised by peripheral
nerve hyperexcitability and encephalopathy, in addition to
sleep disturbance, hallucinations, dysautonomia and pain.
Whether Morvan’s syndrome is a distinct entity or merely
a combination of autoimmune encephalitis and peripheral
nerve hyperexcitability is unclear, but some suggest there
are sufficient differences to consider it a distinct syn-
drome. Limbic dysfunction, such as temporal seizures,
anterograde amnesia or hyperintensities in the MRI are
uncommon in Morvan’s syndrome, except in patients who
are both CASPR2 and LGI1-antibody positive. Both
CASPR2 limbic encephalitis and Morvan’s syndrome are
more common in elderly male patients, but association
with thymoma and other autoimmune diseases is much
more common in Morvan’s syndrome.
Long term follow up
Data on long term outcomes, particularly on cognitive
sequelae, are remarkably scarce in CASPR2 encephalitis
and Morvan’s syndrome, and it is often pooled together
with that of LGI1 encephalitis or under the previous
umbrella designation “VGKC encephalitis”. Partial or full
recovery after immunosuppression is usually the norm in
non-paraneoplastic CASPR2 encephalitis or Morvan’s
syndrome36,57. However, relapses are frequent, particu-
larly in the form of increased seizure activity, and are
usually steroid-responsive.
Mechanisms underlying cognitive impairment
CASPR2, a member of the neurexin family, is a cell
adhesion transmembrane protein first identified in the
VGKC clusters (mainly Kv1.1 and Kv1.2) at the juxta-
paranodes of myelinated neurons59. CASPR2 stabilises the
VGKCs such that antibody-mediated disruption of this
protein causes peripheral hyperexcitability syndromes.
The role of CASPR2 at the CNS synapse, however, is not
well known, but the bulk of data suggests important
functions in synaptic processes and neuronal activity.
CASPR2 was implicated in the trafficking of AMPA
receptors to the synaptic membrane60,61, suggesting that
glutamatergic transmission dysfunction could underpin
the cognitive impairment seen in CASPR2-mediated CNS
disease. Others suggest that CASPR2 has a role in inhi-
bitory hippocampal synapses, and that the antibody-
mediated perturbation of inhibitory interneuron activity
could lead to increased neuronal hyperexcitability and
ultimately to the seizures suffered by these patients62,63.
Like LGI1-antibodies, CASPR2-antibodies are pre-
dominantly of the IgG4 subclass, although IgG1 anti-
bodies can also be present and are potential contributors
to pathology. They too target multiple epitopes, with the
protein’s N-terminal discoidin-like and laminin G1
domains being obligatory epitopes36,64. The mechanisms
by which these antibodies cause disease, however, are still
not completely understood and there have been con-
flicting results in the literature. While some report
absence of CASPR2 internalisation63,65, others suggest
that CASPR2 is indeed internalised35,61,66 by the anti-
bodies. It is possible that the IgG subclass (IgG1 vs IgG4)
titre differences in the CASPR2-IgG preparations used in
these studies, as well as differences in the in vitro systems
used, partially account for these contradicting results.
Those groups that found no evidence for antibody-
mediated internalisation suggest that CASPR2-antibodies
exert their function through interference with the inter-
action between CASPR2 and TAG-163,65. Finally,
CASPR2-antibodies may also exert their pathogenicity by
altering the protein’s known function in AMPAR synaptic
traffic. A recent study showed significant synaptic loss of
AMPARs in cortical neurons incubated with IgG1 and
IgG4 CASPR2 antibodies, while in vivo injection of the
same antibodies in the mouse visual cortex significantly
decreased AMPAR-mediated currents67.
These results suggest that CASPR2 likely has different
functions in different synapses, which would imply dif-
ferent but synergistic effects of the CASPR2-antibodies in
the pathophysiology of encephalitis or Morvan’s syn-
drome. More studies on the pathogenic mechanisms of
CASPR2-antibodies are necessary.
Other neuronal autoantibody-mediated
encephalitis
AMPAR encephalitis
Acute phase
Due to its rarity, the clinical course of AMPAR ence-
phalitis is not yet well characterised. Most studies describe
limbic dysfunction at onset characterised by anterograde
and retrograde amnesia, confusion, psychiatric symptoms
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and seizures68. First described in a series of ten patients, it
was reported to mostly affect older women, often with an
underlying malignancy and high rates of relapse69. The
phenotype has since widened with marked heterogeneity
in presentation observed68,70. However, cognitive dys-
function remains a universally prominent feature and
isolated amnesic syndromes have also been observed with
a focal impairment to anterograde memory70,71. Indeed, in
a review of 18 cases there was evidence of cognitive
impairment in all, ranging from anterograde memory
impairments and executive dysfunction to generalised
confusion68. A recent systematic review identified 55
patients with AMPAR encephalitis; a diverse phenotype
was observed but amnesia was recognised as the most
common clinical symptom71. However, amnesia at onset
was also associated with greater diagnostic delays, high-
lighting the need for improved recognition of the symp-
tomatic profile associated with AMPAR encephalitis.
Long term follow-up
There are limited data available on the neuropsycholo-
gical outcomes of AMPAR encephalitis patients. Case
reports have described considerable neurocognitive
improvement at follow-up with a third achieving com-
plete recovery, but this has yet to be characterised
quantitatively72. Although in general outcomes appear
favourable, psychiatric symptoms or fulminant encepha-
lopathy at onset is associated with poor prognosis at fol-
low up70,72. In a case report, significant memory
impairment was found to persist 1 year after disease onset,
accompanied by hippocampal atrophy, persistent hippo-
campal hypermetabolism in 18FDG PET imaging and
ongoing epileptic activity on EEG73.
Mechanisms underlying cognitive impairment
AMPARs are glutamate-gated ion channels composed
of combinations of the tetrameric subunits GluA1–4.
AMPARs mediate much of the rapid, excitatory neuro-
transmission in the brain and are integral to LTP74. The
composition of subunits has important consequences for
the role of AMPAR in synaptic plasticity and typically
AMPAR antibodies target GluA1 and GluA2 subunits75.
AMPAR antibodies cause reductions in AMPAR expres-
sion with changes to their synaptic localisation through
receptor internalisation and degradation69,76. Reductions
in AMPAR-mediated currents are seen with alterations in
the patterns of action potential firing and an increase in
intrinsic excitability of neurons likely due to a compen-
satory decrease in inhibitory synaptic transmission75,76.
Haselmann et al. demonstrated antibody-mediated inter-
nalisation of GluA2-containing AMPARs with compen-
satory insertion of mostly GluA1-containing AMPARs77.
The subsequent LTP impairments were hypothesised to
be secondary to the reduced availability of extrasynaptic
AMPAR, on which LTP is dependent77,78. Alongside the
LTP changes, they found in vivo impairments to learning
and memory; this was the first animal model to recapi-
tulate the severe memory impairments typical of AMPAR
encephalitis77.
Although ubiquitous, GluA1/2 and GluA2/3 are parti-
cularly expressed in the hippocampal and limbic regions,
and as such these regions are particular targets for
AMPAR antibodies69. Indeed, in the vast majority brain
MRI is abnormal in the acute phase, often showing
bilateral temporal lobe enhancement, reflecting areas of
greatest AMPAR density71. Given AMPARs are found
throughout the brain, albeit at lower concentrations than
in the limbic regions, autoantibody binding in other
regions could account for the marked heterogeneity seen
in clinical profile, with the more generalised distribution
also underpinning the global atrophy and hypometabo-
lism reported in some cases of AMPAR encephalitis79.
GABAAR encephalitis
GABAAR antibody-mediated encephalitis has a broad
clinical phenotype affecting all ages of both sexes80,81. The
largest case series to date confirmed seizures as the most
frequent symptom with altered cognition evident in two-
thirds of patients81. While the clinical phenotype has yet
to be fully characterised, greater variability in presentation
is evident with memory deficits not ubiquitous and cases
without seizures also described82,83. It is possible that the
variation in clinical presentation of GABAAR antibody
encephalitis across these series may be due to the differ-
ences in subunit specificity of cell-based assays used to
detect the antibodies. Studies using the α1 and β3 sub-
units80,81,84 have tended to find a more restricted phe-
notype than those using the α1, β2 and γ2 subunits82,
although differences may also reflect the different nature
of the patient populations whose samples were tested in
these studies.
Mechanisms underlying cognitive impairment
GABA receptors are the major mediator of inhibitory
synaptic transmission in the CNS. GABAA receptors are
ligandgated chloride ion channels, underpinning fast
synaptic inhibition, while GABAB receptors are G-protein
coupled receptors modulating slower inhibitory trans-
mission. Autoantibodies to GABAARs are generally IgG1
and those which target the extracellular epitope of the γ2,
α1 and β3 subunit cause reduced synaptic and extra-
synaptic GABAAR with consequent reductions in inhibi-
tory postsynaptic currents in vitro80,85. Mutations to the
GABAAR reducing expression levels cause generalised
epilepsies but there are, as yet, no animal studies which
demonstrate the impact of GABAAR antibodies in vivo
86.
However, in the acute phase brain MR imaging is com-
monly abnormal; 77% show multifocal, asynchronous grey
Gibson et al. Translational Psychiatry          (2020) 10:304 Page 9 of 17
and white matter changes most often in the temporal and
frontal lobes81. These widespread changes reflect the
extensive distribution of GABAAR which, along with the
likely presence of additional anti-neuronal antibodies,
may underpin the heterogeneity in presentation of
GABAAR encephalitis
87.
GABABR encephalitis
GABABR encephalitis was first described in a case series
of 15 patients characterised by seizures and memory
deficits88. Older adults are most affected and there is a
strong association with small cell lung cancer, occurring
in up to 50% of patients and associated with poorer out-
comes89. While more recent clinical descriptions have
expanded the clinical phenotype, cognitive impairment
and seizures remain the central symptoms, almost uni-
versally affecting patients in the acute phase but the
nature of neuropsychological impairments have not been
examined in detail90. Interestingly, this recent case series
identified a subset of patients with GABABR encephalitis
presenting with a “rapidly progressive dementia” with
subacute cognitive impairment in the absence of sei-
zures90. Prognosis is often poor, with a median survival of
17 months, and the long term outcomes for GABABR
encephalitis have yet to be studied90.
Mechanisms underlying cognitive impairment
Antibodies associated with GABABR encephalitis are
predominantly of the IgG1 subclass targeting the extra-
cellular domain of the B1 subunit88. Autoantibodies to the
GABABR act to inhibit channel function rather than
internalise or deplete cell surface receptor levels91. In line
with the clinical phenotype, knockout GABAB1R mice
exhibit spontaneous seizures with marked memory
impairment92. The GABAB receptor is mainly expressed
in hippocampus, amygdala, thalamus, and cerebellum
reflecting the common MTL abnormalities seen in ima-
ging during the acute phase of encephalitis93.
Beyond autoimmune encephalitis
While the impact of neuronal autoantibodies on cog-
nition is well established within each encephalitic syn-
drome, their role outside this context is less clear.
However, there is accumulating evidence to indicate these
antibodies (particularly NMDAR antibodies) may be of
relevance outside clinically defined encephalitis, in
patients without evidence of frank encephalopathy. All
NMDAR antibodies, irrespective of immunoglobulin class
and donor source, demonstrate pathological potential;
in vitro (and, to a lesser extent, in vivo) instigating
NMDAR internalisation and dysfunctional glutamatergic
signalling94. However, this is not equivalent to asserting
that all such antibodies are potentially encephalitogenic
and this distinction must be held in mind95.
Serum NMDAR antibodies, of uncertain clinical rele-
vance, are found in appreciable numbers in healthy con-
trols, which is a challenge to the view that they are
universally pathological. In one such study serum
NMDAR antibodies of all isotypes occurred at an overall
frequency of about 10%, increasing with age but not dif-
fering according to disease status; NMDAR IgG remained
relatively rare however, detectable in around 1%. Similar
results were reported for antibodies to other antigens,
although these were much less common than NMDAR
antibodies96. Notably, different assays also appear to have
different sensitivities for detection of neuronal auto-
antibodies. Live cell-based assays, in which sera or CSF is
applied to recombinant HEK cells expressing the antigen
of interest before fixation, appear to detect many more
positive specimens than do fixed assays, in which the sera
or CSF is applied after fixation. Nonetheless, while live
CBAs do detect antibodies that demonstrably bind their
target, the clinical relevance of the results is less clear—
that is, the increased analytical sensitivity of these assays
may come at the expense of clinical specificity97,98.
In part because of the issue of non-specificity of serum
autoantibodies to neuronal antigens, diagnostic criteria
for autoimmune CNS disorders place much emphasis on
paraclinical investigations which are required to deter-
mine the clinical relevance of a positive antibody, such as
MRI or EEG. Neither in consensus criteria for auto-
immune encephalitis99 or for autoimmune psychosis100
can a positive serum antibody on its own lead to a diag-
nosis of probable antibody-mediated disorder.
It has been suggested that some aspect of blood-brain
barrier permeability is one factor which can determine the
clinical relevance of a positive serum antibody, with
numerous studies showing autoantibody-mediated neu-
ropsychiatric symptoms to be dependent on blood-brain
barrier permeability101–103. Indeed, in SLE rodent models,
infusion of NMDAR antibodies (targeting the NR2 rather
than NR1 subunit) only caused cognitive impairment
where the blood-brain barrier was disrupted104. It also
remains possible that impaired blood-brain barrier
integrity, or other mechanisms, could allow formation of
antibodies in patients with neuronal decline via recogni-
tion of these neuronal antigens for the first time105. We
review the evidence for a role of autoantibody-associated
cognitive impairment in various common disorders.
Cancer
Paraneoplastic neurological syndromes are immune-
mediated disorders triggered by tumours driving the
immunization process. Many of the autoimmune
encephalitis-associated antigens are expressed by
tumours, and paraneoplastic neurological syndromes can
be associated with neuronal autoantibodies targeting
these tumour-expressed neuronal antigens (such as
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NMDAR antibodies with teratomas and CASPR2 anti-
bodies with thymomas). However, the association
between tumours, neuronal antibodies and cognition has
recently been explored beyond the context of limbic
encephalitis. In a retrospective study, neuronal antibodies
were observed in almost a quarter of cancer patients
tested and cognitive deficits were found to be significantly
more common in those with a positive serum neuronal
antibody106. The antibodies most commonly identified
were IgA or IgM NMDAR antibody, and the level of
cognitive impairment was related to the degree of blood-
CSF barrier disruption as indexed by the cerebrospinal
fluid/serum albumin quotient106. These findings were
then replicated and extended in a prospective study of
melanoma patients107. Importantly, all patients under-
went a comprehensive cognitive assessment that was
performed blinded to antibody status. Melanoma patients
with neuronal autoantibodies (mostly serum IgA and IgM
NMDAR antibodies) showed more than threefold higher
odds for cognitive impairment than melanoma patients
without antibodies. Furthermore, the degree of cognitive
impairment was correlated with the titre of NMDAR IgM
or IgA antibody107. Affected cognitive domains included
memory, attention and executive function indicating
neuronal autoantibodies may have a role as both a
pathophysiological factor and a potential biomarker for
cognitive impairment107. However, future studies are
needed to determine whether the observed cognitive
impairments in antibody-positive patients are specific to
cancer and whether antibodies themselves are pathogenic
or rather indicate pathophysiological states leading to
cognitive decline.
Viral encephalitis
It is now established that neuronal autoimmunity—
principally to NMDAR but other antigens have also been
implicated—can be initiated by herpes simplex encepha-
litis (HSE)108,109. In up to 90% of so-called ‘relapses’ of
HSE, where the clinical picture is frequently dominated by
cognitive dysfunction, the aetiology is now understood to
represent a “secondary autoimmune encephalitis”
responsive to immunotherapy; indeed autoimmune
encephalitis is thought to occur in around a third of HSE
patients58. One obvious factor potentially responsible for
initiation of autoimmunity is the gross neuronal
destruction and subsequent epitope exposure caused by
HSV infection. Indeed, other CNS viral infections are also
known to initiate neuronal autoantibody production109.
However, history of non-encephalitic HSV infection is
also more common in NMDAR encephalitis110 suggesting
molecular mimicry may also play a role111. Interestingly in
one study, even in patients who did not develop frank
encephalopathy after HSV infection, CSF NMDAR anti-
bodies were interpreted to be predictive of the degree of
improvement in cognitive function in the recovery phase
of HSE112. However, in this study, there was no difference
in cognitive performance between NMDAR antibody
positive and negative patients at any time during follow-
up; rather, there was only a significantly greater
improvement of cognitive scores in the antibody negative
group, driven by recovery from a worse baseline perfor-
mance for these patients compared to that of the NMDAR
antibody positive patients. Moreover, the relatively
impaired performance of NMDAR antibody negative
patients at baseline was driven by four outliers with par-
ticularly impaired performance112. Given the significant
impact of post-HSE cognitive impairment on functioning
and quality of life, and the lack of clarity of these results,
attempts at clarifying the possible prognostic significance
of NMDAR antibodies in this patient group are of con-
tinued interest. Overall it appears that secondary neuronal
autoimmunity following other kinds of brain tissue
damage could have a role in shaping the extent of cog-
nitive dysfunction following an acute event. One such
obvious example of brain tissue damage, amenable to
study by virtue of its frequency, is stroke.
Stroke
Serum neuronal antibodies are detected in up to one-
fifth of patients following acute stroke113. However, there
is as yet no consensus regarding the relevance of these
antibodies in this clinical population. One recent study
did not find any association of serum neuronal antibody
seropositivity with functional outcome or clinical features
in acute stroke114. Another large study did not find an
association with seroprevalence per se, unless the group
was stratified by NMDAR antibody titre, when high
antibody titre was found to correlate with poor functional
outcomes115. In addition, NMDAR antibody seropositive
patients had an increased risk of secondary vascular
events or death. The integrity of the blood-brain barrier
may also be relevant in stroke: in patients with acute
ischaemic stroke, NMDAR antibodies were associated
with larger stroke lesions in patients with a “leaky” blood-
brain barrier, as indicated by APOE4 status, and con-
versely, in patients with an intact blood-brain barrier
NMDAR antibodies were associated with smaller stroke
lesion size113. Thus, the relationship between auto-
antibodies and outcomes following stroke is not linear but
serum NMDAR antibodies may be of particular relevance
where they are found at high titre and/or with a com-
promised blood-brain barrier. Although functional out-
comes are in part driven by cognitive status following
stroke, to date no study has investigated an association
between antibody seropositivity and quantitative cognitive
outcomes following stroke. This would be methodologi-
cally challenging due to the inherent variability in cogni-
tive outcomes with lesion heterogeneity but could offer
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the potential for new insights into the impact of neuronal
antibodies outside encephalitis.
Psychiatric disorders
Psychiatric symptoms are hallmarks of many of the
autoimmune encephalitic syndromes, in some cases
occurring in the absence of the other clinical symp-
toms116. This has caused considerable interest in investi-
gating a potential role for neuronal antibodies in the
pathogenesis of psychiatric syndromes. Various case-
control studies have produced conflicting results, but a
systematic review and meta-analysis found that serum
NMDAR antibodies were three times as common in
patients with schizophrenia, schizoaffective disorder,
bipolar affective disorder or major depressive disorder
compared to controls117,118. This finding was supported
by a more recent large case-control study indicating that
serum NMDAR antibodies were more prevalent in
patients with first episode psychosis than in the healthy
controls, although this was not the case for the other
antibodies tested; LGI1, GABAAR and VGKC-complex
119.
However, in the psychiatric patient population, the clin-
ical characteristics between antibody positive and anti-
body negative patients appear similar and to date the
clinical significance of this increased prevalence is
unclear120.
Cognitive impairment is a central feature of schizo-
phrenia with the dysfunction extending across domains of
memory, attention and executive function121. These def-
icits occur before the onset of psychosis and remain stable
throughout the course of the disease122,123. Glutamate
receptor hypofunction has been hypothesised to underlie
this cognitive impairment and more recently NMDAR
autoimmunity has been implicated. Indeed, a recent study
found that first episode psychosis patients with schizo-
phrenia who had a positive serum NMDAR antibody
exhibited greater cognitive impairments in all domains
relative to controls124. Furthermore, serum antibody level
was inversely correlated with scores in verbal and learning
memory, working memory and speed of processing. In
this clinical population, the pathogenicity of NMDAR
antibodies also appears to relate to blood-brain barrier
integrity101,125. Increased blood-brain barrier permeability
is known to associate with Toxoplasma gondii exposure in
human cohorts and NMDAR antibody seropositivity (to
the NR2 subunit) in schizophrenia was associated with
higher degrees of cognitive impairment where it coexisted
with Toxoplasma gondii exposure125. While these find-
ings are of great interest, no firm conclusions can be made
without replication on a larger scale.
Dementia
Neuronal autoantibodies have also been detected at
relatively high frequencies in a number of dementia
syndromes; in one study increased prevalence of NMDAR
antibodies, predominantly IgA and IgM, was demon-
strated across all types of dementia (16% vs 2% in con-
trols)126. While it remains unclear whether these
autoantibodies have a primary pathogenic role or reflect a
response to neuronal damage, there is some evidence to
support a possible role in mediating cognitive symptoms.
Patients with neurodegenerative disease such as Parkin-
son’s disease have been found to have serum NMDAR
antibody frequencies in the range of controls unless there
is evidence of dementia e.g., dementia with Lewy bodies
or Parkinson’s disease dementia126. Although no such
association was found in a more recent study of Parkin-
son’s disease with dementia, given the cognitive impair-
ment in the studied group was modest (mean MMSE 25)
this merits replication127.
The prevalence of serum NMDAR antibodies is not
uniformly distributed across dementia subtypes. Dis-
proportionately high frequencies of positive antibodies
(>60%) are found in ‘unclassified’ or ‘atypical’ demen-
tias102,126. These patients frequently had subacute onset
with rapid progression or fluctuation and an inflammatory
CSF, often showing reversibility when treated with
immunotherapy126,128. In a recent meta-analysis, we
reported that both IgG and IgA/M serum NMDAR anti-
bodies were more prevalent in atypical dementias vs
healthy controls, while there was no difference for all-
cause dementia. However, the total number of studies was
small and “atypicality” was inconsistently defined and in
some studies may have been done so post-hoc, necessi-
tating caution in interpretation of this intriguing result129.
The term “autoimmune dementia” has been proposed
to describe this subacute cognitive impairment responsive
to immunotherapy and, while its prevalence is unclear,
there is growing suspicion that many cases may go
undiagnosed, overlooked as primary neurodegenerative
dementias130. In a study of 56 patients, a third of those
who responded to immunotherapy, with notable
improvements in all cognitive domains, had been initially
diagnosed with a neurodegenerative or prion disorder131.
Numerous case reports have illustrated the potential for
antibodies to produce a phenocopy of established
dementia syndromes, with misdiagnoses seen in cases of
both NMDAR and LGI1 encephalitis mimicking atypical
neurodegenerative dementias11,37. Given the reversible
nature of autoimmune dementia, potential misdiagnoses
of this nature could be catastrophic and all efforts to avoid
them must be made.
Neurodevelopmental implications
Placental transfer of IgG antibodies during gestation is a
well-established phenomenon, with these antibodies also
having the potential to penetrate the foetal blood-brain
barrier during specific developmental windows132,133. It is
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therefore perhaps unsurprising that in utero autoantibody
exposure has been implicated neurodevelopmentally as a
pathogenic factor altering the cognitive development of
the foetus. CASPR2 is known to have a critical role in
neurodevelopment, is highly expressed in the proliferating
zones and is necessary for dendritic spine development
and arborisation, integral to neural circuit assembly134. In
CNTNAP2 knockout mice, which lack the predominant
CASPR2 isoform, there are abnormalities in neuronal
migration and reduced inhibitory GABAergic neurons
causing a typical autistic phenotype with spontaneous
seizures135. This phenotype is mirrored in paediatric
patients with homozygous CNTNAP2 mutations who lack
CASPR2136. Mice exposed to CASPR2 antibody in utero
show abnormal cortical migration and development with
reduced glutamatergic synapses, increased microglial
activation and decreased hippocampal inhibitory neu-
rons137,138. The offspring showed subsequent long-term
behavioural sequelae with repetitive behaviour and
impairments in sociability and flexible learning137,138.
Prevalence of CASPR2 antibodies was markedly higher in
a subgroup of mothers with autistic children (37%) than in
the control groups (8–12%)137. These results were not
replicated in a Danish cohort study but CASPR2 anti-
bodies were found more frequently in the mothers of
children with “mental retardation or disorders of psy-
chological development”139. This study did not find a
significant association between maternal NMDAR anti-
bodies and child cognitive development but a murine
model has demonstrated reduced density of NMDAR in
neonates of mothers with NMDAR antibodies with
associated neuropathological changes and greater post-
natal mortality and chronic increased hyperactivity140. An
association between maternal lupus, with anti-dsDNA
antibodies cross-reacting with the NR2A/NR2B subunits
of the NMDAR, and neurocognitive problems in the off-
spring has been reported, with the offspring showing
deficits in behaviour, memory and learning141. dsDNA-
specific NMDAR antibodies injected into pregnant dams
caused thinned, disorganised cortex in offspring with
subsequent cognitive impairments142. While there is no
evidence of overlap with the NR1 NMDAR antibodies
seen in encephalitis it illustrates the potential for these
antibodies to also exert an effect on neurodevelopment143.
Conclusions and future directions
Each neuronal antibody exerts a distinct mechanistic
effect and while the downstream effects all include cog-
nitive dysfunction, the affected domains vary between
subtype. However, there is much work to be done in fully
characterising both the acute and chronic impairments of
the encephalitic syndromes; current descriptions tend to
be mostly qualitative and for the less common subtypes
data is sparse.
Outside of encephalitis, pathogenicity of the neuronal
antibodies may be contingent on factors including the
integrity of the blood-brain barrier. Where this is com-
promised there is often evidence of secondary cognitive
dysfunction; we postulate that blood-brain barrier dis-
ruption modulates much of the heterogeneity seen in the
impact of neuronal antibodies outside of encephalitis. The
site of autoantibody production may be equally important.
In autoimmune encephalitis, it is likely that ongoing
peripheral germinal centre reactions generate antigen-
specific B cells. Subsequently, antigen-secreting cells that
have differentiated from these B cells likely access the
CNS, resulting in intrathecal production of pathogenic
IgG144. It is not at all clear that the same process is
occurring in the non-encephalitic situations described in
this review. Indeed, blood-brain barrier disruption might
be an important factor in some of the situations described
above precisely because there is no intrathecal production
of pathogenic antibodies. Furthermore, the description of
unmutated yet functional (and potentially pathogenic,
despite low affinity) NMDAR antibodies raises the possi-
bility that, outside of the encephalitis context, the clinical
relevance and/or pathogenicity of neuronal autoantibodies
might in fact arise from the so-called ‘healthy’ naïve B cell
repertoire145. Differences in epitope specificity, antibody
titres and duration of interaction and initial immunising
stimulus may also all have relevance in distinguishing
encephalitis cases from non-encephalitis cases where the
antibodies nonetheless may have some pathogenic role. An
alternative, and underexplored, perspective is that neuro-
nal autoantibodies (particularly “natural” antibodies with
different binding properties) could have an adaptive phy-
siological role; recent animal (and to some extent human)
work suggests that NMDAR antibodies could be produced
in response to stress as a mechanism to reduce anxiety/
depressive behaviours, possibly via NMDAR antagon-
ism146. It is conceivable that there is an analogous role in
preventing, for example, excitotoxicity-mediated neuronal
damage and cognitive impairment in some circumstances,
although this remains to be explored.
Crucially, there is very little evidence currently for or
against the possibility that immunotherapy could be an
effective treatment in any of these non-encephalitis
situations; the main notable exceptions are in cases of
atypical or “autoimmune dementia”—and in some of
these cases the demarcation from autoimmune encepha-
litis is far from clear126,128,131. The possibility that specific
immunotherapies could have a role in treating cancer-
associated cognitive impairment, or as a treatment to
prevent the progression of cognitive impairment in neu-
ronal antibody-positive post-HSV encephalitis patients,
for example, warrants further evaluation.
Non-IgG NMDAR antibodies, in particular, have been
implicated in the cognitive impairment seen in a
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multitude of disorders including cancer, dementia and
schizophrenia. While NMDAR antibodies have been
shown to universally have pathogenic potential94, the
clinical consequence may vary with isotype. It is well
established that the IgG isotype can cause NMDAR
encephalitis while IgA NMDAR antibodies have been
implicated in a more insidious cognitive impairment128.
Indeed, the frequencies of NMDAR antibodies detected in
dementia, cancer and stroke are more than twofold
greater for IgA or IgM isotypes than IgG102,106,113. We
suggest that these isotypes may be relevant for under-
standing cognitive impairment outside of encephalitis.
While the potential exists for all the neuronal antibodies
described to impact cognition, further work is needed to
characterise this. In the future this could pave the way for
novel, immunologically-based therapeutic options to treat
cognitive impairment, with potentially transformative
implications.
Acknowledgements
T.A.P. was supported in a Clinical Research Training Fellowship by the Wellcome
Trust (Grant Number: 105758/Z/14/Z) and in a clinical lectureship by the National
Institute for Health Research (NIHR). The views expressed are those of the author
(s) and not necessarily those of the NIHR or the Department of Health and Social
Care. C.F. was support by the Deutsche Forschungsgemeinschaft (DFG, German
Research Foundation; grant numbers 327654276 (SFB 1315) and FI 2309/2-1) and
the German Federal Ministry of Education and Research (BMBF; Grant Numbers
13GW0212A, 13GW0206D and 01GM1908D).
Author details
1Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, London, UK. 2University of Cambridge,
Cambridge, UK. 3Department of Basic and Clinical Neuroscience, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, London, UK.
4MRC Centre for Neurodevelopmental Disorders, King’s College London,
London, UK. 5Department of Neurology, Charité – Universitätsmedizin Berlin,
Berlin, Germany. 6Berlin School of Mind and Brain, Humboldt-Universität zu
Berlin, Berlin, Germany. 7Department of Psychosis Studies, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 27 January 2020 Revised: 29 July 2020 Accepted: 30 July 2020
References
1. Schmidt-Wilcke, T. et al. GABA-from inhibition to cognition: emerging con-
cepts. Neuroscientist 24, 501–515 (2018).
2. Sohal, V. S. & Rubenstein, J. L. R. Excitation-inhibition balance as a framework
for investigating mechanisms in neuropsychiatric disorders. Mol. Psychiatry
24, 1248–1257 (2019).
3. Zhou, S. & Yu, Y. Synaptic E-I balance underlies efficient neural coding. Front
Neurosci. 12, 46 (2018).
4. Kornau, H. C. et al. Human cerebrospinal fluid monoclonal LGI1
autoantibodies increase neuronal excitability. Ann. Neurol. 87, 405–418
(2020).
5. Kreye, J. et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate
receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain.
139, 2641–2652 (2016).
6. Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome
in patients with anti-NMDA receptor encephalitis: an observational cohort
study. Lancet Neurol. 12, 157–165 (2013).
7. Nicolle, D. C. M. & Moses, J. L. A systematic review of the neuropsychological
sequelae of people diagnosed with anti N-methyl-D-aspartate receptor
encephalitis in the acute and chronic phases. Arch. Clin. Neuropsychol. 33,
964–983 (2018).
8. McKeon, G. L. et al. Cognitive outcomes following anti-N-methyl-D-aspartate
receptor encephalitis: a systematic review. J. Clin. Exp. Neuropsychol. 40,
234–252 (2018).
9. Kuroda, T. et al. Autobiographical age awareness disturbance syndrome in
autoimmune limbic encephalitis: two case reports. BMC Neurol. 15, 238
(2015).
10. Savage, S. A., Irani, S. R., Leite, M. I. & Zeman, A. Z. NMDA receptor antibody
encephalitis presenting as transient epileptic amnesia. J. Neuroimmunol. 327,
41–43 (2019).
11. Abe, K. & Chiba, Y. A case of treatable dementia with Lewy bodies
remarkably improved by immunotherapy. J. Neuroimmunol. 330, 35–37
(2019).
12. Gibson, L. L. et al. The psychiatric phenotype of anti-NMDA receptor ence-
phalitis. J. Neuropsychiatry Clin. Neurosci. 31, 70–79 (2019).
13. Finke, C. et al. Cognitive deficits following anti-NMDA receptor encephalitis. J.
Neurol. Neurosurg. Psychiatry 83, 195–198 (2012).
14. McKeon, G. L. et al. Cognitive and social functioning deficits after anti-N-
methyl-D-aspartate receptor encephalitis: an exploratory case series. J. Int
Neuropsychol. Soc. 22, 828–838 (2016).
15. Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor
encephalitis. J. Neurosci. 30, 5866–5875 (2010).
16. Moscato, E. H. et al. Acute mechanisms underlying antibody effects in anti-N-
methyl-D-aspartate receptor encephalitis. Ann. Neurol. 76, 108–119 (2014).
17. Mikasova, L. et al. Disrupted surface cross-talk between NMDA and Ephrin-B2
receptors in anti-NMDA encephalitis. Brain: a J. Neurol. 135, 1606–1621
(2012).
18. Planaguma, J. et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor anti-
body effects on memory and neuroplasticity. Ann. Neurol. 80, 388–400
(2016).
19. Zhang, Q. et al. Suppression of synaptic plasticity by cerebrospinal fluid from
anti-NMDA receptor encephalitis patients. Neurobiol. Dis. 45, 610–615 (2012).
20. Wang, X. et al. Neuronal NMDAR currents of the hippocampus and learning
performance in autoimmune anti-NMDAR encephalitis and involvement of
TNF-alpha and IL-6. Front Neurol. 10, 684 (2019).
21. Kersten, M. et al. Novel object recognition in rats with NMDAR dysfunction in
CA1 after stereotactic injection of anti-NMDAR encephalitis cerebrospinal
fluid. Front Neurol. 10, 586 (2019).
22. Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic
neurotransmission by ketamine: a novel step in the pathway from NMDA
receptor blockade to dopaminergic and cognitive disruptions associated
with the prefrontal cortex. J. Neurosci. 17, 2921–2927 (1997).
23. Monaghan, D. T., Yao, D. & Cotman, C. W. L-[3H]Glutamate binds to kainate-,
NMDA- and AMPA-sensitive binding sites: an autoradiographic analysis. Brain
Res 340, 378–383 (1985).
24. Finke, C. et al. Functional and structural brain changes in anti-N-methyl-D-
aspartate receptor encephalitis. Ann. Neurol. 74, 284–296 (2013).
25. Peer, M. et al. Functional connectivity of large-scale brain networks in
patients with anti-NMDA receptor encephalitis: an observational study.Lancet
Psychiatry 4, 768–774 (2017).
26. Finke, C. et al. Structural hippocampal damage following anti-N-methyl-D-
aspartate receptor encephalitis. Biol. Psychiatry 79, 727–734 (2016).
27. Phillips, O. R. et al. Superficial white matter damage in anti-NMDA receptor
encephalitis. J. Neurol. Neurosurg. Psychiatry 89, 518–525 (2018).
28. Jones, B. E. et al. Autoimmune receptor encephalitis in mice induced by
active immunization with conformationally stabilized holoreceptors. Sci.
Transl. Med. 11, eaaw0044 (2019).
29. Buckley, C. et al. Potassium channel antibodies in two patients with reversible
limbic encephalitis. Ann. Neurol. 50, 73–78 (2001).
30. Irani, S. R. et al. Antibodies to Kv1 potassium channel-complex proteins
leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2
Gibson et al. Translational Psychiatry          (2020) 10:304 Page 14 of 17
in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia.
Brain 133, 2734–2748 (2010).
31. Lang, B. et al. Intracellular and non-neuronal targets of voltage-gated
potassium channel complex antibodies. J. Neurol. Neurosurg. Psychiatry 88,
353–361 (2017).
32. van Sonderen, A. et al. The relevance of VGKC positivity in the absence of
LGI1 and Caspr2 antibodies. Neurology 86, 1692–1699 (2016).
33. Irani, S. R. et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic
encephalitis. Ann. Neurol. 69, 892–900 (2011).
34. Binks, S. N. M. et al. LGI1, CASPR2 and related antibodies: a molecular evo-
lution of the phenotypes. J. Neurol. Neurosurg. Psychiatry 89, 526–534 (2018).
35. Arino, H. et al. Anti-LGI1-associated cognitive impairment: presentation and
long-term outcome. Neurology 87, 759–765 (2016).
36. Joubert, B. et al. Characterization of a subtype of autoimmune encephalitis
with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal
fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 73, 1115–1124
(2016).
37. Li, X., Yuan, J., Liu, L. & Hu, W. Antibody-LGI 1 autoimmune encephalitis
manifesting as rapidly progressive dementia and hyponatremia: a case
report and literature review. BMC Neurol. 19, 19 (2019).
38. Marquetand, J. et al. Slowly progressive LGI1 encephalitis with isolated late-
onset cognitive dysfunction: a treatable mimic of Alzheimer’s disease. Eur. J.
Neurol. 23, e28–e29 (2016).
39. Butler, C. R. et al. Persistent anterograde amnesia following limbic ence-
phalitis associated with antibodies to the voltage-gated potassium channel
complex. J. Neurol. Neurosurg. Psychiatry 85, 387–391 (2014).
40. Finke, C. et al. Evaluation of cognitive deficits and structural hippocampal
damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies.
JAMA Neurol. 74, 50–59 (2017).
41. Hanert, A. et al. Hippocampal dentate gyrus atrophy predicts pattern
separation impairment in patients with LGI1 encephalitis. Neuroscience 400,
120–131 (2019).
42. van Sonderen, A. et al. Anti-LGI1 encephalitis: clinical syndrome and long-
term follow-up. Neurology 87, 1449–1456 (2016).
43. Thompson, J. et al. The importance of early immunotherapy in patients with
faciobrachial dystonic seizures. Brain: a J. Neurol. 141, 348–356 (2018).
44. Irani, S. R. et al. Faciobrachial dystonic seizures: the influence of immu-
notherapy on seizure control and prevention of cognitive impairment in a
broadening phenotype. Brain 136, 3151–3162 (2013).
45. Ohkawa, T. et al. Autoantibodies to epilepsy-related LGI1 in limbic ence-
phalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA
receptors. J. Neurosci. 33, 18161–18174 (2013).
46. Lalic, T., Pettingill, P., Vincent, A. & Capogna, M. Human limbic encephalitis
serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic
transmission. Epilepsia 52, 121–131 (2011).
47. Petit-Pedrol, M. et al. LGI1 antibodies alter Kv1.1 and AMPA receptors
changing synaptic excitability, plasticity and memory. Brain 141, 3144–3159
(2018).
48. Ramberger, M. et al. Distinctive binding properties of human monoclonal
LGI1 autoantibodies determine pathogenic mechanisms. Brain J Neurol.
https://doi.org/10.1093/brain/awaa104 (2020).
49. Kalachikov, S. et al. Mutations in LGI1 cause autosomal-dominant partial
epilepsy with auditory features. Nat. Genet. 30, 335–341 (2002).
50. Herranz-Perez, V., Olucha-Bordonau, F. E., Morante-Redolat, J. M. & Perez-Tur,
J. Regional distribution of the leucine-rich glioma inactivated (LGI) gene
family transcripts in the adult mouse brain. Brain Res. 1307, 177–194 (2010).
51. Vincent, A. et al. Potassium channel antibody-associated encephalopathy: a
potentially immunotherapy-responsive form of limbic encephalitis. Brain 127,
701–712 (2004).
52. Kotsenas, A. L. et al. MRI findings in autoimmune voltage-gated potassium
channel complex encephalitis with seizures: one potential etiology for mesial
temporal sclerosis. Am. J. Neuroradiol. 35, 84–89 (2014).
53. Miller, T. D. et al. Focal CA3 hippocampal subfield atrophy following
LGI1 VGKC-complex antibody limbic encephalitis. Brain 140, 1212–1219
(2017).
54. Loane, C. et al. Hippocampal network abnormalities explain amnesia after
VGKCC-Ab related autoimmune limbic encephalitis. J. Neurol. Neurosurg.
Psychiatry 90, 965–974 (2019).
55. Heine, J. et al. Beyond the limbic system: disruption and functional com-
pensation of large-scale brain networks in patients with anti-LGI1 ence-
phalitis. J. Neurol. Neurosurg. Psychiatry 89, 1191–1199 (2018).
56. Saint-Martin, M. et al. Contactin-associated protein-like 2, a protein of the
neurexin family involved in several human diseases. Eur. J. Neurosci. 48,
1906–1923 (2018).
57. Irani, S. R. et al. Morvan syndrome: clinical and serological observations in 29
cases. Ann. Neurol. 72, 241–255 (2012).
58. Armangue, T. et al. Frequency, symptoms, risk factors, and outcomes of
autoimmune encephalitis after herpes simplex encephalitis: a prospective
observational study and retrospective analysis. Lancet Neurol. 17, 760–772
(2018).
59. Poliak, S. et al. Juxtaparanodal clustering of Shaker-like K+ channels in
myelinated axons depends on Caspr2 and TAG-1. J. Cell Biol. 162, 1149–1160
(2003).
60. Varea, O. et al. Synaptic abnormalities and cytoplasmic glutamate receptor
aggregates in contactin associated protein-like 2/Caspr2 knockout neurons.
Proc. Natl Acad. Sci. USA 112, 6176–6181 (2015).
61. Fernandes, D. et al. Disrupted AMPA receptor function upon genetic- or
antibody-mediated loss of autism-associated CASPR2. Cereb. cortex 29,
4919–4931 (2019).
62. Pinatel, D. et al. Inhibitory axons are targeted in hippocampal cell culture by
anti-Caspr2 autoantibodies associated with limbic encephalitis. Front Cell
Neurosci. 9, 265 (2015).
63. Saint-Martin, M. et al. Impact of anti-CASPR2 autoantibodies from patients
with autoimmune encephalitis on CASPR2/TAG-1 interaction and Kv1
expression. J. Autoimmun. 103, 102284 (2019).
64. Olsen, A. L. et al. Caspr2 autoantibodies target multiple epitopes. Neurol.(R.)
Neuroimmunol. Neuroinflammation 2, e127 (2015).
65. Patterson, K. R., Dalmau, J. & Lancaster, E. Mechanisms of Caspr2 antibodies
in autoimmune encephalitis and neuromyotonia. Ann. Neurol. 83, 40–51
(2018).
66. Giannoccaro, M. P. et al. Behaviour and neuropathology in mice injected
with human contactin-associated protein 2 antibodies. Brain 142, 2000–2012
(2019).
67. Fernandes, D. et al. Disrupted AMPA Receptor Function upon Genetic- or
Antibody-Mediated Loss of Autism-Associated CASPR2. Cereb Cortex, https://
doi.org/10.1093/cercor/bhz032 (2019).
68. Hoftberger, R. et al. Encephalitis and AMPA receptor antibodies: novel
findings in a case series of 22 patients. Neurology 84, 2403–2412 (2015).
69. Lai, M. et al. AMPA receptor antibodies in limbic encephalitis alter synaptic
receptor location. Ann. Neurol. 65, 424–434 (2009).
70. Joubert, B. et al. Clinical spectrum of encephalitis associated with antibodies
against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor: case series and review of the literature. JAMA Neurol. 72, 1163–1169
(2015).
71. Laurido-Soto, O. et al. Patient characteristics and outcome associations in
AMPA receptor encephalitis. J. Neurol. 266, 450–460 (2019).
72. Samad, N. & Wong, J. Anti-AMPA receptor encephalitis associated with
medullary thyroid cancer. BMJ Case Rep 2018, bcr2018225745. https://doi.
org/10.1136/bcr-2018-225745 (2018).
73. Spatola, M. et al. Serial brain (1)(8)FDG-PET in anti-AMPA receptor limbic
encephalitis. J. Neuroimmunol. 271, 53–55 (2014).
74. Henley, J. M. & Wilkinson, K. A. AMPA receptor trafficking and the
mechanisms underlying synaptic plasticity and cognitive aging. Dialogues
Clin. Neurosci. 15, 11–27 (2013).
75. Gleichman, A. J. et al. Antigenic and mechanistic characterization of anti-
AMPA receptor encephalitis. Ann. Clin. Transl. Neurol. 1, 180–189 (2014).
76. Peng, X. et al. Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies.
Ann. Neurol. 77, 381–398 (2015).
77. Haselmann, H. et al. Human autoantibodies against the AMPA receptor
subunit GluA2 induce receptor reorganization and memory dysfunction.
Neuron 100, 91–105. e109 (2018).
78. Granger, A. J. et al. LTP requires a reserve pool of glutamate receptors
independent of subunit type. Nature 493, 495–500 (2013).
79. Wei, Y. C. et al. Rapid progression and brain atrophy in anti-AMPA receptor
encephalitis. J. Neuroimmunol. 261, 129–133 (2013).
80. Petit-Pedrol, M. et al. Encephalitis with refractory seizures, status epilepticus,
and antibodies to the GABAA receptor: a case series, characterisation of the
antigen, and analysis of the effects of antibodies. Lancet Neurol. 13, 276–286
(2014).
81. Spatola, M. et al. Investigations in GABAA receptor antibody-associated
encephalitis. Neurology 88, 1012–1020 (2017).
Gibson et al. Translational Psychiatry          (2020) 10:304 Page 15 of 17
82. Pettingill, P. et al. Antibodies to GABAA receptor alpha1 and
gamma2 subunits: clinical and serologic characterization. Neurology 84,
1233–1241 (2015).
83. Nikolaus, M. et al. Severe GABAA receptor encephalitis without seizures: a
paediatric case successfully treated with early immunomodulation. European
journal of paediatric neurology: EJPN: official journal of the European Pae-
diatric Neurology. Society 22, 558–562 (2018).
84. O’Connor, K. et al. GABAA receptor autoimmunity: a multicenter experience.
Neurol.(R.) Neuroimmunol. neuroinflammation 6, e552 (2019).
85. Ohkawa, T. et al. Identification and characterization of GABA(A) receptor
autoantibodies in autoimmune encephalitis. J. Neurosci. 34, 8151–8163
(2014).
86. Macdonald, R. L., Kang, J. Q. & Gallagher, M. J. Mutations in GABAA receptor
subunits associated with genetic epilepsies. J. Physiol. 588, 1861–1869 (2010).
87. Nikolaus, M. et al. CSF reactivity in GABAA receptor antibody
encephalitis–Immunocytochemical distribution in the murine brain. Brain
Res. 1704, 249–256 (2019).
88. Lancaster, E. et al. Antibodies to the GABA(B) receptor in limbic encephalitis
with seizures: case series and characterisation of the antigen. Lancet Neurol. 9,
67–76 (2010).
89. Hoftberger, R. et al. Encephalitis and GABAB receptor antibodies: novel
findings in a new case series of 20 patients. Neurology 81, 1500–1506 (2013).
90. van Coevorden-Hameete, M. H. et al. The expanded clinical spectrum of anti-
GABABR encephalitis and added value of KCTD16 autoantibodies. Brain: a J.
Neurol. 142, 1631–1643 (2019).
91. Nibber, A. et al. Pathogenic potential of antibodies to the GABAB receptor.
Epilepsia Open 2, 355–359 (2017).
92. Schuler, V. et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre-
and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31,
47–58 (2001).
93. Cui, J. et al. The gamma-aminobutyric acid-B receptor (GABAB) encephalitis:
clinical manifestations and response to immunotherapy. Int. J. Neurosci. 128,
627–633 (2018).
94. Castillo-Gomez, E. et al. All naturally occurring autoantibodies against the
NMDA receptor subunit NR1 have pathogenic potential irrespective of
epitope and immunoglobulin class. Mol. Psychiatry 22, 1776–1784 (2017).
95. Ehrenreich, H. Autoantibodies against N-methyl-d-aspartate receptor 1 in
health and disease. Curr. Opin. Neurol. 31, 306–312 (2018).
96. Dahm, L. et al. Seroprevalence of autoantibodies against brain antigens in
health and disease. Ann. Neurol. 76, 82–94 (2014).
97. Jezequel, J. et al. Cell- and single molecule-based methods to detect anti-N-
methyl-D-aspartate receptor autoantibodies in patients with first-episode
psychosis from the OPTiMiSE project. Biol. Psychiatry 82, 766–772 (2017).
98. Zandi, M. S. et al. Clinical relevance of serum antibodies to extracellular N-
methyl-d-aspartate receptor epitopes. J. Neurol. Neurosurg. Psychiatry 86,
708–713 (2015).
99. Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis.
Lancet Neurol. 15, 391–404 (2016).
100. Pollak, T. A. et al. Autoimmune psychosis: an international consensus on an
approach to the diagnosis and management of psychosis of suspected
autoimmune origin. Lancet Psychiatry 7, 93–108 (2020).
101. Hammer, C. et al. Neuropsychiatric disease relevance of circulating anti-
NMDA receptor autoantibodies depends on blood-brain barrier integrity.
Mol. Psychiatry 19, 1143–1149 (2014).
102. Busse, M. et al. Dysfunction of the blood-cerebrospinal fluid-barrier and N-
methyl-D-aspartate glutamate receptor antibodies in dementias. Eur. Arch.
Psychiatry Clin. Neurosci. 268, 483–492 (2018).
103. Levin, E. C. et al. Brain-reactive autoantibodies are nearly ubiquitous in human
sera and may be linked to pathology in the context of blood-brain barrier
breakdown. Brain Res. 1345, 221–232 (2010).
104. Kowal, C. et al. Human lupus autoantibodies against NMDA receptors
mediate cognitive impairment. Proc. Natl Acad. Sci. USA 103, 19854–19859
(2006).
105. Dalmau, J., Geis, C. & Graus, F. Autoantibodies to synaptic receptors and
neuronal cell surface proteins in autoimmune diseases of the central nervous
system. Physiol. Rev. 97, 839–887 (2017).
106. Finke, C. et al. High prevalence of neuronal surface autoantibodies asso-
ciated with cognitive deficits in cancer patients. J. Neurol. 264, 1968–1977
(2017).
107. Bartels, F. et al. Neuronal autoantibodies associated with cognitive impair-
ment in melanoma patients. Ann. Oncol. 30, 823–829 (2019).
108. Armangue, T. et al. Herpes simplex virus encephalitis is a trigger of brain
autoimmunity. Ann. Neurol. 75, 317–323 (2014).
109. Pruss, H. Postviral autoimmune encephalitis: manifestations in children and
adults. Curr. Opin. Neurol. 30, 327–333 (2017).
110. Salovin, A. et al. Anti-NMDA receptor encephalitis and nonencephalitic HSV-1
infection. Neurol. Neuroimmunol. Neuroinflammation 5, e458 (2018).
111. Dale, R. C. & Nosadini, M. Infection-triggered autoimmunity: The case of
herpes simplex virus type 1 and anti-NMDAR antibodies. Neurol. Neu-
roimmunol. Neuroinflammation 5, e471 (2018).
112. Westman, G. et al. N-Methyl-D-Aspartate receptor Autoimmunity Affects
Cognitive Performance in herpes simplex encephalitis. Clin. Microbiol. Infect,
https://doi.org/10.1016/j.cmi.2016.07.028 (2016).
113. Zerche, M. et al. Preexisting serum autoantibodies against the NMDAR
subunit NR1 modulate evolution of lesion size in acute ischemic. Stroke
Stroke 46, 1180–1186 (2015).
114. Royl, G. et al. Antibodies against neural antigens in patients with acute stroke:
joint results of three independent cohort studies. J. Neurol. 266, 2772–2779
(2019).
115. Sperber, P. S. et al. Serum anti-NMDA (N-methyl-D-aspartate)-receptor anti-
bodies and long-term clinical outcome after stroke (PROSCIS-B). Stroke 50,
3213–3219 (2019).
116. Kayser, M. S., Titulaer, M. J., Gresa-Arribas, N. & Dalmau, J. Frequency and
characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate
receptor encephalitis. JAMA Neurol. 70, 1133–1139 (2013).
117. Hoffmann, C. et al. Absence of Autoantibodies Against Neuronal Surface
Antigens in Sera of Patients With Psychotic Disorders. JAMA Psychiatry,
https://doi.org/10.1001/jamapsychiatry.2019.3679 (2019).
118. Pearlman, D. M. & Najjar, S. Meta-analysis of the association between N-
methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective
disorder, bipolar disorder, and major depressive disorder. Schizophr. Res. 157,
249–258 (2014).
119. Lennox, B. R. et al. Prevalence and clinical characteristics of serum neuronal
cell surface antibodies in first-episode psychosis: a case-control study. Lancet
Psychiatry 4, 42–48 (2017).
120. Schou, M. & Saether, S. G. NMDA receptor antibodies are found in a small
subgroup of patients with first-episode psychosis, but their clinical relevance
is unknown. Evid. Based Ment. Health 21, e1–e2 (2018).
121. Bowie, C. R. & Harvey, P. D. Treatment of cognitive deficits in schizophrenia.
Curr. Opin. Investig. Drugs 7, 608–613 (2006).
122. Bilder, R. M. et al. Neuropsychology of first-episode schizophrenia: initial
characterization and clinical correlates. Am. J. Psychiatry 157, 549–559 (2000).
123. Rund, B. R. A review of longitudinal studies of cognitive functions in schi-
zophrenia patients. Schizophr. Bull. 24, 425–435 (1998).
124. Tong, J. et al. Elevated serum anti-NMDA receptor antibody levels in first-
episode patients with schizophrenia. Brain Behav. Immun. 81, 213–219 (2019).
125. Kannan, G. et al. Pathogen-mediated NMDA receptor autoimmunity and
cellular barrier dysfunction in schizophrenia. Transl. Psychiatry 7, e1186 (2017).
126. Doss, S. et al. High prevalence of NMDA receptor IgA/IgM antibodies in
different dementia types. Ann. Clin. Transl. Neurol. 1, 822–832 (2014).
127. Hopfner, F. et al. No association between Parkinson disease and auto-
antibodies against NMDA-type glutamate receptors. Transl. Neurodegener. 8,
11 (2019).
128. Pruss, H. et al. IgA NMDA receptor antibodies are markers of synaptic
immunity in slow cognitive impairment. Neurology 78, 1743–1753 (2012).
129. Gibson, L. L. et al. Neuronal surface autoantibodies in dementia: a systematic
review and meta-analysis. J. Neurol. https://doi.org/10.1007/s00415-020-
09825-0 (2020).
130. Flanagan, E. P., Drubach, D. A. & Boeve, B. F. Autoimmune dementia and
encephalopathy. Handb. Clin. Neurol. 133, 247–267 (2016).
131. Flanagan, E. P. et al. Autoimmune dementia: clinical course and predictors of
immunotherapy response. Mayo Clin. Proc. 85, 881–897 (2010).
132. Braniste, V. et al. The gut microbiota influences blood-brain barrier perme-
ability in mice. Sci. Transl. Med. 6, 263ra158 (2014).
133. Palmeira, P. et al. IgG placental transfer in healthy and pathological preg-
nancies. Clin. Dev. Immunol. 2012, 985646 (2012).
134. Anderson, G. R. et al. Candidate autism gene screen identifies critical role for
cell-adhesion molecule CASPR2 in dendritic arborization and spine devel-
opment. Proc. Natl Acad. Sci. USA 109, 18120–18125 (2012).
135. Penagarikano, O. et al. Absence of CNTNAP2 leads to epilepsy, neuronal
migration abnormalities, and core autism-related deficits. Cell 147, 235–246
(2011).
Gibson et al. Translational Psychiatry          (2020) 10:304 Page 16 of 17
136. Rodenas-Cuadrado, P., Ho, J. & Vernes, S. C. Shining a light on CNTNAP2:
complex functions to complex disorders. Eur. J. Hum. Genet. 22, 171–178 (2014).
137. Brimberg, L. et al. Caspr2-reactive antibody cloned from a mother of an ASD
child mediates an ASD-like phenotype in mice.Mol. Psychiatry 21, 1663–1671
(2016).
138. Coutinho, E. et al. Persistent microglial activation and synaptic loss with
behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies
in utero. Acta Neuropathologica 134, 567–583 (2017).
139. Coutinho, E. et al. CASPR2 autoantibodies are raised during pregnancy in
mothers of children with mental retardation and disorders of psychological
development but not autism. J. Neurol. Neurosurg. Psychiatry 88, 718–721
(2017).
140. Jurek, B. et al. Human gestational N-methyl-d-aspartate receptor auto-
antibodies impair neonatal murine brain function. Ann. Neurol. 86, 656–670
(2019).
141. Urowitz, M. B. et al. Neurocognitive abnormalities in offspring of mothers
with systemic lupus erythematosus. Lupus 17, 555–560 (2008).
142. Lee, J. Y. et al. Neurotoxic autoantibodies mediate congenital cortical
impairment of offspring in maternal lupus. Nat. Med. 15, 91–96 (2009).
143. Hirohata, S. & Tanaka, K. Differential expression of antibodies to NMDA
receptor in anti-NMDA receptor encephalitis and in neuropsychiatric sys-
temic lupus erythematosus. Lupus Sci. Med. 6, e000359 (2019).
144. Makuch, M. et al. N-methyl-D-aspartate receptor antibody production from
germinal center reactions: Therapeutic implications. Ann. Neurol. 83, 553–561
(2018).
145. Wenke, N. K. et al. N-methyl-D-aspartate receptor dysfunction by
unmutated human antibodies against the NR1 subunit. Ann. Neurol. 85,
771–776 (2019).
146. Pan, H. et al. Multiple inducers and novel roles of autoantibodies against the
obligatory NMDAR subunit NR1: a translational study from chronic life stress
to brain injury. Mol. Psychiatry, https://doi.org/10.1038/s41380-020-0672-1
(2020).
147. Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med. 378,
840–851 (2018).
Gibson et al. Translational Psychiatry          (2020) 10:304 Page 17 of 17
